Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Michael R.M. McGuigan x
  • Refine by Access: All Content x
Clear All Modify Search
Restricted access

Michael R.M. McGuigan, Roger Bronks, Robert U. Newton, John C. Graham, and David V. Cody

Peripheral arterial disease (PAD) is associated with impaired lower extremity function. This study investigated differences in PAD and control participants and the relationship between lower limb strength and clinical measures of PAD severity. Participants were evaluated by 6-min-walk distance, normal and maximal walking speed over 10 m, isometric plantar-flexion strength, and dynamic dorsi-/plantar-flexion strength. Hemodynamic measures of the lower limbs were recorded at rest and after maximal treadmill testing. PAD participants walked significantly less far during the 6-min walk, and there were large differences in normal and maximal walking speeds. Small to moderate differences were found for isometric plantar-flexion strength. In the diseased legs of the PAD participants, resting systolic hallux photoplethysmography was significantly correlated with isokinetic plantar-flexion strength and onset of claudication pain during the 6-min-walk test. In addition to confirming the documented loss of walking endurance, these data suggest that loss of strength of the plantar flexors is associated with increasing PAD impairment.

Restricted access

William J. Kraemer, Ana L. Gómez, Nicholas A. Ratamess, Jay R. Hoffman, Jeff S. Volek, Martyn R. Rubin, Timothy P. Scheett, Michael R. McGuigan, Duncan French, Jaci L. VanHeest, Robbin B. Wickham, Brandon Doan, Scott A. Mazzetti, Robert U. Newton, and Carl M. Maresh

Objective:

To determine the effects of Vicoprofen®, ibuprofen, and placebo on anaerobic performance and pain relief after resistance-exercise-induced muscle damage.

De-sign:

Randomized, controlled clinical study.

Setting:

University human-performance/sports-medicine laboratory.

Participants:

36 healthy men.

Methods and Measures:

After baseline testing (72 h), participants performed an eccentric-exercise protocol. Each was evaluated for pain 24 h later and randomly assigned to a Vicoprofen (VIC), ibuprofen (IBU), or placebo (P) group. Postexercise testing was performed every 24 h for 4 d.

Results:

Significantly greater muscle force, power, and total work were observed in VIC than in P (P < .05) for most time points and for IBU at 48 h.

Conclusions:

Anaerobic performance is enhanced with VIC, especially within the first 24 h after significant muscle-tissue damage. The greater performances observed at 48 h might be a result of less damage at this time point with VIC treatment.